Eduardo Bravo

Eduardo was appointed as Chairman of the Board in November 2020.

He has over 25 years of senior management and board experience in the biopharmaceutical sector, having held the position of CEO at Nordic Nanovector, TiGenix and Cellerix. As CEO at TiGenix, he oversaw several financing rounds, the company’s IPO on NASDAQ, and its eventual acquisition by Takeda.

Earlier in his career, Eduardo held several senior management positions at Sanofi-Aventis and SmithKline Beecham.

He is currently Chairman of the Board at Vivet Therapeutics and a Board Member at Sutura Therapeutics.

Eduardo was President of the European Biopharmaceutical Enterprises Board of Directors between 2016 and 2018, and was also member of the Executive Committee of Alliance for Regenerative Medicine. He holds a degree in Business Administration and an MBA from INSEAD.